Medical oncology research

The Medical Oncology Research Unit at Canberra Hospital has been operating since 1979. It is involved in the conduct of clinical trials in cancer patients exploring new agents and methods of treating malignancies.

The Medical Oncology Research Unit at Canberra Hospital has been operating since 1979.

It is involved in the conduct of clinical trials in cancer patients exploring new agents and methods of treating malignancies.

Affiliations

The Research Unit has affiliations with national cooperative trial organisations such as the Australian and New Zealand Breast Cancer Study Group (ANZBCTG), the Australasian Gastrointestinal Trials Group (AGITG), the Australian Lung Trials Group (ALTG), the Australian Gynaecological Oncology Group (AGOG)and the Australian New Zealand Urogenital and Prostate Cancer Trials Group.

We are also part of the Greater Southern Area Health Service Clinical Trials Network along with Border Medical Oncology and the Riverina Cancer Centre supported by a grant from the Cancer Institute NSW.

Through these trials important new therapies may be accessed before they become licensed, reimbursed or widely available.

They are necessary to find out if new treatments are more effective than those currently accepted as being the best available.

All clinical trial protocols are approved and monitored by the ACT Health Human Research Ethics Committee. All trials abide with the ethical principles outlined by the Declaration of Helsinki and adhere to the ICH Harmonised Tripartite guidelines for Good Clinical Practice.

Funding for the research comes from four key sources: external granting bodies, fund raising, the pharmaceutical industry and private donations. The continued financial support of clinical trials is essential if progress is to be made in the treatment and control of cancer.

Support

We are most grateful for the support of the Cancer Council ACT, the Monaro Committee for Cancer Research and the National Cancer Research Foundation.

Tax deductible donations and bequests would be most gratefully accepted to help support the activities of the Research Unit.

Contact us

Contact Olive Doig on (02) 5124 3856.

Clinical trials

BioGrid: BioGrid Federated Database for the Installation and Implementation of a Database Node for Bio21 Molecular Medicine Informatics Model

ALT GIST: A Randomised Phase II Trial of Imatinib alternating with Regorafenib compared to Imatinib alone for the first line treatment advanced gastro-intestinal stromal tumour

ELIMINATE: Oestrogen lowering intervention may increase neoadjuvant therapy efficacy. Randomised Phase II trial of neoadjuvant chemotherapy +/- concurrent aromatase inhibitor endocrine therapy to downstage large oestrogen receptor positive breast cancer

BR.31: A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MED14736 in Completely Resected Non-Small Cell Lung Cancer

PROSPER: A Phase 4, Randomized, Double-Blind, Placebo Controlled Study of Continued Enzalutamide Treatment beyond Progression in Patients with Chemotherapy-Naïve, Metastatic-Castration Resistant Prostate Cancer:

TABITHA: Study of the clinical outcomes and analysis of antiHER2 therapy use in treatment of metastatic HER2 positive breast cancer

Genetic and cellular analysis of autoimmune and inflammatory disease: Investigation of immune modulating cancer treatments

ECHO: A Phase III randomised controlled trial of exercise during chemotherapy for patients commencing first line treatment for ovarian cancer.

Cardiometabolic Risk Factor: The prevalence of weight gain and cardiometabolic disease in women with breast cancer: identifying trends from diagnosis to remission

TRACC: Prospective Study of clinical outcomes and analysis of bevacizumab use in metastatic colorectal cancer: BioGrid Project

A biomarker study to develop a multicomponent diagnostic screen for the detection of circulating tumour cells (CTC) and cancer stem cells (CSC) using peripheral blood

Complete Freund’s Adjuvant: Phase I Study of Complete Freund’s Adjuvant (CFA) in Patients with Refractory and Relapsed Solid Tumours

Lonsurf/Servier: An Open-label early access phase IIIb study of trifluridine / tipiracil (S 95005/TAS-102) in patients with a pretreated metastatic colorectal cancer

Epiaxis 001-0716: A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination with Phenelzine in Metastatic or Inoperable Locally Advanced Breast Cancer

DYNAMIC: Circulating Tumour (ct) DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colorectal Cancer

SAUL: An Open Label, Single Arm, Multicentre, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract. Protocol MO29983.

VERTU: A Randomised Phase II study of VELiparib + Radiotherapy (RT) with adjuvant Temozolomide (TMZ) + veliparib versus standard RT + TMZ followed by TMZ in patients with newly diagnosed glioblastoma (GBM) with Unmethylated O (6)-methylguanine-DNA methyltransferase (MGMT)

INTEGRATE II: A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

ARCHES: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Clinical Research Staff

Dr Yu Jo Chua, Director, Medical Oncology Research Unit

Olive Doig, RN, Clinical Trials Manager.
Anne Ryan, RN, Clinical Trials Coordinator
Suzie Taylor RN, Clinical Trials Coordinator
David Ilchef, Administrative Assistant

Phone (02) 5124 3688.

Collaborative Associates

A/Professor Christine Hemmings RGON, BHB, MBChB, FRCPA, St John of God Pathology, Subiaco WA.

Dr Alesia Ivashkevich, MSc, PhD, Cancer Research Laboratory, Department of Radiation Oncology, Canberra Hospital.

Dr Anneke Blackburn, BSc PhD, John Curtin School of Medical Research

Professor Sudha Rao, BSc PhD, Molecular and Cellular Biology, Centre for Research in Therapeutics Solutions, University of Canberra

A/Professor Kate Pumpa,BSc MSc PhD, Sport and Exercise Science, Faculty of Health, University of Canberra.

Professor Afaf Girgis, Translation Cancer Research Centre, Ingham Insitute for Applied Medical Research, University of NSW.

Research Grants Held

Prof R. Stuart-Harris. Prospective evaluation of cognitive impairment in women receiving adjuvant chemotherapy for early breast cancer. The Canberra Region Medical Foundation

Stuart-Harris R. The Development of a Clinical Palliative Index for the Treatment of Advanced Cancer. The Private Practice Fund, The Canberra Hospital

Stuart-Harris R. Coping Styles and Severity of Toxicity from Adjuvant Chemotherapy for Early Breast Cancer or Colorectal Cancer. Cancer Council ACT.

Yip D. A Cancer Clinical Trials Research Programme in the ACT. Cancer Council ACT.

Yip D, Budge M, Taupin D, Nolan C. Installation and implementation of Bio21:MMIM (Molecular Medicine Informatics Model now known as BioGrid Australia) in Canberra. TCH Radiation Oncology Private Practice Trust Fund.

Haydon A, Zalcberg J, Walpole E, Yip D, Price T, Howard K, Jefford M. Short Course Oncology Therapy- A study of Adjuvant Chemotherapy in Colorectal Cancer by the CACTUS and OCTO Groups. Cancer Australia Priority driven Collaborative Cancer Research Scheme.

Yip D, Dahlstrom J, Jain S, Barry P, Carpenter J, Clarke C. Westmead Millenium Institute, University of Sydney. The Breast Cancer Tissue Bank: establishment of collection site for collection, storage and transfer of human blood and tissue samples in the ACT.

Rao S, Jans D, Forward J, Dahlstrom J, Yip D. Epigenetic regulation by PKC-theta in human breast cancer stem cells. NHMRC Project Grant

Scott R, Balleine R,Clarke C, Dahlstrom J, Forbes J, Marsh D, Pathmanathan N, Simpson P,Yip D, Zeps N.  Extending the strategic importance of the Australian Breast Cancer Tissue Bank to facilitate breast cancer research. National Breast Cancer Foundation National Infrastructure Grant

Identification of Melanoma Circulating Tumour Cells (CTC)/Cancer Stem Cells (CSC) burden and the role of novel epigenetic enzymes in melanoma cancer biology

Medical Oncology Research Publications

Journal Publications

Craft PS, Zhang Y, Brogan J, Tait N, Buckingham JM. Implementing clinical practice guidelines: a community-based audit of breast cancer treatment. Australian Capital Territory and South Eastern New South Wales Breast Cancer Treatment Group. Med J Aust. 2000 Mar 6;172(5):213-6.

Armstrong BK, Leong DC. Measuring cancer care. Aust N Z J Surg. 2000 Jan;70(1):1-2.

Cohn DA. Stuart-Harris R. Isolated central nervous system relapse of non-seminomatous germ cell tumour of the testis. A case report and review of the literature. Oncology. 61(3):184-8, 2001.

Strickland AH, Karapetis CS, Yip D, Harper PG. Adjuvant Chemotherapy for Gastro-oesophageal Cancer with Epirubicin, Cisplatin and Fluorouracil: a single centre experience (letter). Clinical Oncology 13(1) 66, 2001.

Yip D, Craft P. Colorectal carcinoma: Current Issues in Management. Current Therapeutics, 42 (7),45-50, 2001.

Yip D, Steer C, El-Nawab M, Van Der Walt, Harper P. Collecting duct carcinoma of the kidney associated with the sickle cell trait. International Journal of Clinical Practice 2001, 55;1-3.

Mann L, Baldwin D, Yip D. Alopecia: The importance of body image.Geriatric Medicine 2001, 31 (4) 19-24.

Gordard N, Yip D. The treatment of lung cancer. Geriatric Medicine 2001, 31 (7) 30-33.

Yip D, Karapetis CS, Steer C . The management of small cell lung cancer. Expert Review of Anticancer Therapy 2001 1 (2); 89-102.

Karapetis CS, Yip D, Virik K, Strickland AH, Ryder K, Cowling M, Harper PG. Epirubicin, cisplatin and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site. Medical Oncology 2001, 18(1):23-32.

Karapetis CS. Strickland AH, Yip D, Van Der Walt J, Harper PG. PET and PLAP in Suspected Testicular Cancer Relapse: Beware Sarcoidosis. Annals of Oncology, 2001, 12 (10)1485-1488.

Halford S, Yip D, Karapetis CS, Steger A, Khawaja H, Harper PG. A phase II study evaluating the tolerability and efficacy of Caelyx (liposomal doxorubicin, Doxil) in the treatment of unresectable pancreatic carcinoma.Annals of Oncology 2001, 12(10), 1399-1402.

Steer C, Yip D. Symptom Palliation in advanced esophageal cancer. Current Therapeutics 2002, 43 (3); 33-35.

Steer C, Yip D. Symptom Palliation in advanced esophageal cancer. New Ethicals 2002, (4); 49-51.

Shadbolt B, Barresi J, Craft P. Self-Rated Health as a Predictor of Survival Among Patients With Advanced Cancer Journal of Clinical Oncology. 2002: 2514-2519.

Davis AJ, Tannock IF Tumor physiology and resistance to chemotherapy: repopulation and drug penetration. Cancer Treat Res. 2002;112:1-26.

Davis A.J., Chapman W., Hedley D.W., Oza A.M., Tannock I.F: Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer. Cytometry 2003 Jan;51A(1):1-6.

Hawkins,CA, Blasioli J, McCarthy CS, Yip D, Hurwitz MD, Jain S, Cook MC. Recent onset granulomatous common variable immunodeficiency in an 88 year woman. Pathology, 2003, 35 (1) 81-82.

Yip D, Karapetis C, Strickland AH, Steer C, Holford C, Knight S, and Harper P. A dose-escalating study of oral eniluracil/5-fluorouracil plus oxaliplatin in patients with advanced gastrointestinal malignancies. Annals of Oncology 2003, 14: 864-866

Karapetis CS, Strickland AH, Yip D, Steer C, Harper PG. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up. Internal Medicine Journal 2003 33: 427-435.

Burns C, Dixon T, Broom D, Smith WT, Craft PS. Family caregiver knowledge of treatment intent in a longitudinal study of patients with advanced cancer. Support Care Cancer, 2003, 11:629-637.

Barresi M, Shadbolt B, Byrne, Stuart-Harris R. The development of the Canberra symptom scorecard: a tool to monitor the physical symptoms of patients with advanced tumours. BMC Cancer 2003, 3:32.

Yip D, Allen R, Ashton C, Jain S. Radiation induced ulceration of the stomach secondary to hepatic embolization with radioactive yttrium microspheres in the treatment of metastatic colon cancer. Journal of Gastroenterology and Hepatology 2004, 19 (3): 347-349.

Gibbs P, Chao M, Jones I, Yip D. Current Evidence Supports the Use of Adjuvant Radiotherapy in Selected Patients with Rectal Cancer. Australian New Zealand Journal of Surgery 2004, 74 (3), 152-157.

Chua Y, Steer C, Yip D. Recent Advances in Small Cell Lung Cancer Cancer Treatment Reviews 2004,30(6), 521-543.

Hughes B, Yip D, Goldstein D, Waring P, Beshay V, Chong G. Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report BMC Cancer 2004, 4:74.

Armstrong K, O'Connell DL, Leong D, Spigelman AD, Armstrong BK. The New South Wales colorectal cancer care survey- Part 1 surgical management.
The Cancer Council 2004.

McGrath DR, Leong DC, Armstrong BK, Spigelman AD. Continuing Medical Education. Management of colorectal cancer patients in Australia: The National Colorectal Cancer Care Survey. Australian New Zealand Journal Surgery 2004; 74:55-64.

Hughes B, Yip D, Chao M, Gibbs P, Carroll S, Goldstein D, Burmeister B, Karapetis C. Audit of post-operative chemoradiotherapy as adjuvant for resected gastroeosophageal adenocarcinoma: an Australian multicentre experience. Australian and New Zealand Journal of Surgery 2004 74 (11):951-5.

Burns CM, Dixon T, Smith WT, Craft PS. Patients with advanced cancer and family caregivers' knowledge of health and community services: a longitudinal study. Health Soc Care Community. 2004 ;12(6):488-503.

Lim L, Gibbs P, Yip D, Shapiro J, Dowling R, Smith D, Little W, Liechtenstein M. A prospective study of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable primary or secondary hepatic malignancies. Internal Medicine Journal 2005, 35(4); 222 227.

Stuart-Harris R, Odell H, Sturgiss E. Adjuvant chemotherapy for early breast cancer: Is cyclophosphamide, methotrexate and 5-fluorouracil still the standard? Asia Pacific Journal of Clinical Oncology 2005l 1(1),13-24.

Davis AJ, Craft P, Yip D. Australian Patterns of Practice Survey in the Adjuvant Systemic Treatment of Early Breast Cancer. Asia Pacific Journal of Oncology 2005 1 (1): 25-3.

Burns CM, Craft PS, Roder DM. Does emotional support influence survival? Findings from a longitudinal study of patients with advanced cancer. Support Care Cancer. 2005 May;13(5):295-302.

Yip D, Goldstein D.Adding irinotecan to first-line gemcitabine improves tumour response in advanced pancreatic cancer Abstracted from: Rocha Lima CM, Green MR, Rotche R et al, Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumour response rate J Clin Oncol 2004; 22:3776-83 (Commentary). Cancer Treatment Reviews 2005; 35 (4): 236-41.

Hughes BG, Stuart-Harris R. Docetaxel-induced myositis: report of a novel side-effect. Intern Med J. 2005 Jun;35(6):369-70.

Buchanan G, Craft PS, Yang M, Cheong A, Prescott J, Jia L, Coetzee GA, Tilley WD. PC-3 cells with enhanced androgen receptor signaling: a model for clonal selection in prostate cancer. Prostate. 2004 Sep 1;60(4):352-66.

Clarke S, Boyer M, Millward M, Underhill C, Moylan E, Yip D, White S, Childs A, Beale P, Latz J, Suri A, Iglesias J. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 2005; 49 (3): 401-12.

Grimpen F Yip D, McArthur G, Waring P, Goldstein D, Loughrey M, Beshay V, Chong G. Resistance to Imatinib Mesylate associated with low FDG-avidity on PET and acquired exon 17 mutation in Gastrointestinal Stromal Tumour (GIST). Lancet Oncology 2005; 6 (11); 851-855.

Lim L, Yip D, Shapiro JD, Dowling R, Smith D, Little A, Bailey W, Lietchenstein M ,Gibbs. A prospective study of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy BMC Cancer 2005, 5:132.

Koshy A, Buckingham JM, Zhang Y, Craft P, Dahlstrom JE, Tait N; Surgical management of invasive breast cancer: a 5-year prospective study of treatment in the Australian Capital Territory and South-Eastern New South Wales. ANZ J Surg. 2005 Sep;75(9):757-61

Craft PS, Burns CM, Smith WT, Broom DH. Knowledge of treatment intent among patients with advanced cancer: a longitudinal study. : Eur J Cancer Care (Engl). 2005;14(5):417-2

McGrath DR, Leong DC, Gibberd R, Armstrong B, Spigelman AD. Continuing Medical Education:Surgeon and hospital volume and the management of colorectal cancer patients in Australia. ANZ J Surg 2005; 75:901-10

Bromley J, Hughes BGM, Leong DCS, Buckley NA. Life-Threatening Interaction Between Complementary Medicines: Cyanide Toxicity Following Ingestion of Amygdalin and Vitamin C. Ann Pharmacotherapy 2005; 39(9):1566-9.

Armstrong K, O'Connell DL, Leong D, Yu XQ, Spigelman AD, Armstrong BK. The New South Wales Colorectal Cancer Care Survey Part 2 - Chemotherapy Management. The Cancer Council NSW 2005.

Steer CB, Chrystal K, Cheong KA, Galani E, Marx G, Strickland AH, Yip D, Lofts F, Gallagher G, Thomas H, Harper PG. Gemcitabine and Oxaliplatin followed by Paclitaxel and Carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets: The GO-First Study. Gynaecologic Oncology 2006 103;439-445.

Tan TH, Stevenson B, Yip D. Docetaxel induced nasal septal perforation. Internal Journal of Medicine 2006 36(7):471-2.

Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database of Systematic Reviews 2006, Issue 3.

Burns CM, Broom DH, Smith WT, Dear K, Craft PS.Fluctuating awareness of treatment goals among patients and their caregivers: a longitudinal study of a dynamic process. Support Care Cancer, 2007, 15(2):187-96.

Tinker AV, Gebski V, Fitzharris B, Buck M, Stuart-Harris R, Beale P, Goldrick A, Rischin D. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01. Gynecol Oncol. 2007 Mar;104(3):647-53.

Young, J. Leong, D. Armstrong, K. et al, Concordance with national guidelines for colorectal cancer care in New South Wales: a population-based patterns of care study, Medical Journal of Australia, 2007;186, 292-295.

Davis AJ, Brew S, Gebski VJ, Lewis CR, Moylan E, Parnis FX, Ackland SP. Multicenter phase II study of combination chemotherapy with capecitabine and intravenous vinorelbine in patients with pretreated metastatic breast cancer Asia-Pacific Journal of Clinical Oncology 2007, 3 (1), 37-43.

Harnett P, Buck M, Beale P, Goldrick A, Allan S, Fitzharris B, de Souza P, Links M, Kalimi G, Davies T, Stuart-Harris R. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. Int J Gynecol Cancer. 2007 Mar-Apr;17(2):359-66.

Kanthan GL,Jayamohan J,Yip D,Conway RM. Management of metastatic carcinoma of the uveal tract: an evidence-based analysis. Clinical & Experimental Ophthalmology 2007, 35(6): 553-565.

Ruzich M, Ryan B, Owen C, Delahunty A, Stuart-Harris R. A Prospective Evaluation of Cognitive Function in Patients with Early Breast Cancer Receiving Adjuvant Chemotherapy. Asia Pac J Clin Oncol 3: 125-133, 2007

Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, Griffiths A, Parker S, Houssami N. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 43:1905-1917, 2007.

Burns CM, Broom D, Dear K, Smith WT, Craft PS. Fluctuating knowledge of treatment goal amongst patients and their caregivers: a longitudinal study of a dynamic process. Support Care Cancer, 15(2):187-96, 2007.

Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferative Factors in Early Breast Cancer: A Systematic Review and Meta-Analysis of 85 studies in 32,825 Patients. The Breast, 2008 Apr 30.

Pranavan G, Goldstein D,Yip D. Response of Carney's triad-related metastatic gastrointestinal stromal tumor to sunitinib. Asia Pac J Clin Oncol, 4(3),170-4, 2008.

Chua YJ, Zalcberg JR.Pancreatic cancer--is the wall crumbling?Ann Oncol.19(7):1224-30,2008.

Zalcberg JR, Desai J, Mann B, Fox S, Goldstein D, McArthur G, Clark M, Yip D. Consensus approaches to best practice management of gastrointestinal stromal tumors. Asia Pac J Clin Oncol, 4 (4), 188-198, 2008.

Chua YJ, Zalcberg JR.Progress and challenges in the adjuvant treatment of stage II and III colon cancers.Expert Rev Anticancer Ther;8(4):595-604, 2008.

Snyder RS, Boyle FM, Chan A, Craft PS, De Boer R, Mainwaring PN, McCarthy NJ, Wilcken NR. Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic Her2-positive breast cancer. Asia Pac J Clin Oncol, 5 (1), 4-16, 2009.

Hemmings, C, Broomfield A, Bean E, Whitehead M, Yip D. Immunohistochemical Expression of EGFR in Colorectal Carcinoma Correlates with High- But Not Low-Level Gene Amplification, as Demonstrated by CISH. Pathology 2009, 41 (4): 356-360.

Hoy, J, Neeman T,Stuart-Harris R,Davis A.Risk of venous thromboembolism in patients receiving adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide for early breast cancer. Asia-Pac J Clin Oncol 5 (2) 129-136, 2009.

Wang S, Merlin T, Kreisz F, Craft P, Hiller JE. Cost and cost-effectiveness of digital mammography compared with film-screen mammography in Australia. Aust N Z J Public Health.2009 Oct;33(5):430-6.

Thewes B, Butow P, Stuart-Harris R; Greater Southern Area Health Service Screening Collaborative Group.Does routine psychological screening of newly diagnosed rural cancer patients lead to better patient outcomes? Results of a pilot study. Aust J Rural Health. 2009 Dec;17(6):298-304.

Tan TH, Hemmings C, Stafford-Bell M, Robson S, Yip D. The successful management of two pregnancies with metastatic gastrointestinal stromal tumours. Asia Pacific Journal of Clinical Oncology 2009 5(3) 187-192.

Stuart-Harris R, Shadbolt B, Palmqvist C, Chaudri Ross HA.The prognostic significance of single hormone receptor positive metastatic breast cancer: an analysis of three randomised phase III trials of aromatase inhibitors.Breast. 2009 18(6):351-5.

Stuart-Harris, R, Shah B, Craft P. Adjuvant Chemotherapy for Early Breast Cancer: Current Status and Historical Perspective. Asia Pacific Journal of Oncology & Hematology 2009 1(3),35-42.

Stuart-Harris R, Davis A.Optimal adjuvant endocrine therapy for early breast cancer.Womens Health (Lond Engl). 2010 6(3):383-98

Chua YJ, Michael M, Zalcberg JR, Hicks RJ, Goldstein D, Liauw W, Price T.Antitumor effect of somatostatin analogs in neuroendocrine tumors.J Clin Oncol.20;28(3), 2010.

Chua YJ, Barbachano Y, Cunningham D, Oates JR, Brown G, Wotherspoon A, Tait D, Massey A, Tebbutt NC, Chau I.Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.Lancet Oncol, 11 (3),241-8,2010.

Tan TH, Pranavan G, Haximolla HZ ,Yip D. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies. Asia Pacific Journal of Clinical Oncology 2010 6(1) 5-18.

Craft PS, Buckingham JM , Dahlstrom JE, Beckmann KR, Zhang YP, Stuart-Harris R , Jacob G, Roder D, Tait N. Variation in the management of early breast cancer in rural and metropolitan centres: Implications for the organisation of rural cancer services. Breast, 2010 19(5)396-401.

Stuart-Harris R, Davis A.Optimal adjuvant endocrine therapy for early breast cancer.Womens Health (Lond Engl). 2010 May;6(3):383-98.

Karapetis CS, Cheong KA, Yip D, Strickland AH, Steer C, Marx G, Yip S, Chrystal L, Harper PG. A phase I/II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil (5FU) and sodium folinate (ECSF) in patients with advanced oesophago-gastric carcinoma. Asia Pacific Journal of Clinical Oncology 2010, 6(1);298-305.

Chua YJ.Pathological complete response: still a relevant endpoint in rectal cancer? Lancet Oncol. 2010 Sep;11(9):807-8.

Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebski VJ, Lewis CR, Levi JA, Boyer MJ, Gurney H, Craft P, Boland AL, Simes RJ, Toner GC.Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.J Natl Cancer Inst. 2010 Aug 18;102(16):1253-62.

Okines AF, Ashley SE, Cunningham D, Oates J, Turner A, Webb J, Saffery C, Chua YJ, Chau I. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.J Clin Oncol. 2010 Sep 1;28(25):3945-50.

Talaulikar D, Tridgell D, Leong D, Dahlstrom JE,Cherian M, Prosser I, Sunderland K. Novel therapeutic option for orbital atypical lymphoid hyperplasia. 2010, 38(9),892-894.

Kosmider S, Tan TH, Yip D, Dowling R, Lichtenstein M, Gibbs P, Radioembolization in Combination with Systemic Chemotherapy as First-line Therapy for Liver Metastases from Colorectal Cancer, Journal of Vascular and Interventional Radiology, 2011 22 (6); 780-786.

Goel S, Chirgwin J, Francis P, Stuart-Harris R, Dewar J, Mileshkin L, Snyder R, Michael M, Koczwara B.Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.Breast. 2011 Apr;20(2):101-10.

Beckmann KR, Buckingham J, Craft P, Dahlstrom JE, Zhang Y, Roder D, Stuart-Harris R.Clinical characteristics and outcomes of bilateral breast cancer in an Australian cohort.Breast. 2011 Apr;20(2):158-64.

Webber K, Cooper A, Kleiven H, Yip D, Goldstein D. Management of metastatic renal cell carcinoma in the era of targeted therapies. Internal Medicine Journal 2011 41 (8); 594-605.

Rezo A, Dahlstrom J, Shadbolt B, Rodins K, Zhang Y, Davis A. Tumor Size and Survival in Multicentric and Multifocal Breast Cancer. The Breast 2011; 20:259-263

Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, Mudan S, Brown G, Khan A, Wotherspoon A, Strimpakos AS, Thomas J, Compton S, Chua YJ, Chau I.A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.Annals of Oncology. 2011 Sep;22(9):2042-8.

Subramaniam K, Tucker K, Craft P, Pavli P. Should patients be screened for hereditary cancer syndromes before starting anti-TNF-á therapy? Inflamm Bowel Dis. 2011 Nov;17(11):E151-2.

Thewes B, Butow P, Bell ML, Beith J, Stuart-Harris R, Grossi M, Capp A, Dalley D; FCR Study Advisory Committee. Fear of cancer recurrence in young women with a history of early-stage breast cancer: a cross-sectional study of prevalence and association with health behaviours. Support Care Cancer. 2012 Nov;20(11):2651-9.

Grimison P, Phillips F, Butow P, White K, Yip D, Sardelic F, Underhill C, Tse R, Simes R, Turley K, Goldstein D. Are Visiting Oncologists Enough? A Qualitative Study of the Needs of Australian Rural and Regional Cancer Patients and Health Professionals. Asia Pacific Journal of Clinical Oncology 2013 9 (1) 93-95.

Field K, Wong HL, Shapiro J, Kosmider S, Tie J, Bae S, Yip D, McKendrick J,Nott L, Desai J, Harold M, Lipton L, Stefanou G, Lim L, Parente P, Gibbs P.Developing a national database for metastatic colorectal cancer management:Perspectives and challenges. Internal Medicine Journal 2013 43 (11) 1224-1231.

Behm EC, Beckmann KR, Dahlstrom JE, Zhang Y, Cho C, Stuart-Harris R, Craft P, Rezo A, Buckingham JM.Surgical margins and risk of locoregional recurrence in invasive breast cancer: An analysis of 10-year data from the Breast Cancer Treatment Quality Assurance Project. Breast. 2013 22(5): 839-844.

Malik L, Hemmings C, Beshay V, Fox S, Yip D. Metastatic gastrointestinal stromal tumour of the ileum with dual primary c-KIT mutations. Pathology 2013 45(6): 604-6.

Hovey E, de Souza P, Marx G, Parente P, Rapke T, Hill A, Bonaventura A, Michele A, Craft P, Abdi E, Lloyd A; on behalf of the MOTIF investigators.Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.Support Care Cancer. 2013 Dec 17.

Malik L, Chua Y, Butt NS, Yip D. Single institutional series of neuroendocrine tumours manage in the Australian Capital Territory. (2016) Asia Pacific Journal of Clinical Oncology, 12(1), 133-140.

Hemmings C, Yip D. The Changing Face of GIST: Implications for Pathologists Pathology 2014 46(2):141-8.

Ransom D, Wilson K, Fournier M, Simes RJ, Gebski, Yip D, N. Tebbutt N, Karapetis CS, Ferry D, Gordon S. TJ. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Annals of Oncology 2014 25 (1) 117-21

Kuo J, Hawkins C, Yip D. Treatment outcomes of rapid desensitisation protocols for chemotherapeutic agents and monoclonal antibodies following hypersensitivity reactions. Internal Medicine Journal 2014 2014, 44 (5) 442-449

Yip D, Zalcberg J,Ackland S, Barbour A, Desai J, Fox S, Kotasek D, McArthur G, B Smithers B, Controversies in the management of gastrointestinal stromal tumour. Asia Pacific Journal of Clinical Oncology 2014,10 (3): 216-27.

Kuo J, Parakh S, Yip D. Regorafenib induced hyperammonemic encephalopathy. Journal of Clinical Pharmacy & Therapeutics 2014,39(4):446-8.

Sommeijer DW, Karapetis CS, Zalcberg JR, Tu D, Jonker DJ, Simes J, Tebbutt N, Yip D, Price TJ, O’Callaghan CJ. The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. Acta Oncologica 2014,53(7):877-84.

Tejani N, Cooper A, Rezo A, Pranavan G, Yip D. Numb Chin Syndrome: A case series of a clinical syndrome associated with malignancy. Journal of Medical Imaging and Radiation Oncology 2014, 58(6):700-5.

Nguyen D, Siraj S, Ngu C,Bennett G, Pranavan G. An Unusual Case of Oesophageal Adenocarcinoma Presenting with Subcutaneous Metastases.J Gastrointest Canc 2014.DOI 10.1007/s12029-014-9614-y

Sjoquist K, Chantrill L, Nagrial A, Chin A, O’Connor C, Hemmings C, Johns A, Chang D, Chou A, Palic M, Biankin A,Yip D. Personalising pancreas cancer treatment:when tissue is the issue. World Journal of Gastroenterology 2014,20 (24):7849-7863.

Leong D, Rai R, Nguyen B, Lee A, Yip D. Advances in Adjuvant Systemic Therapy of Non-Small Cell Lung Cancer. World Journal of Clinical Oncology 2014, 5(4):633-645.

Kuo J, Tazbirkova A, Allen R, Kosmider S, Gibbs P, Yip D. Serious hepatic complications of selective internal radiation therapy with yttrium-90 microsphere radioembolization for unresectable liver tumours. Asia Pacific Journal of Clinical Oncology 2014, 10 (3): 266-272

Malik L, Kuo J, Yip D, Mejia A, How well Informed is the Informed Consent for Cancer Clinical Trials? Clinical Trials 2014, 11 (6):686-8.

Parakh S, Piggin A, Neeman T, Mitchell I, Crispin P, Davis A, Outcomes of Haematology/Oncology patients admitted to Intensive Care Unit (ICU) at The Canberra Hospital (TCH). Internal Medicine Journal, 2014, 44(11):1087-94.

Chan A, Shannon C, De Boer R, Baron-Hay S, Redfern A, Bauwens A, Craft P, Webb S, Townsend A, Kotasek D. Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer. Asia Pacific Journal of Clinical Oncology, 2014,10(4):368-375.

Parakh S, Gananadha S, Allen R, Yip D. Cholecystitis as a complication of hepatic implantation of radioactive yttrium resin microspheres for metastatic cancer. (2012) Asia-Pacidic Journal of Clinical Oncology, 8(2), 30-34.

Brulé SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. European Journal Cancer. 2015 15, 1405-1414.

Turner N, Wong H, Field K, Wong R, Shapiro J, Yip D, Nott L, Tie J, Kosmider S, Tran B, Desai J, McKendrick J, Zimet A, Richardson G, Iddawela M, Gibbs P. Defining and measuring variation in the quality of care delivered to patients with metastatic colorectal cancer in routine practice Asia Pacific Journal of Clinical Oncology 2015, DOI: 10.1111/ajco.12355.

Lakhanpal R, Yoong J, Joshi S, Yip D, Mileshkin L, Marx GM, Hovey EJ , Della Fiorentina SA, Venkateswaran L, Tattersall MHN,  Liew MS, Field K, Singal N, Steer CB. Geriatric assessment of older patients with cancer in Australia – a multicentre audit. Journal of Geriatric Oncology 2015 6 (3) 185-193.

Roohullah A Hui-Li Wong HL, Sjoquist KM, Gibbs P, Field K, Tran B, Shapiro J Mckendrick J, Yip D, Nott L, Gebski V, Ng W, Chua W, Price T, Tebbutt N, Chantrill L. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. World Journal of Gastroenterology 2015, 21 (17) 5352-8.

Carlino MS, Kwan V, Miller DK, Saunders CAB, Yip D, Nagrial AM, Tomlinson J ,Grimmond SM, Scolyer RA, Kefford RF, Biankin AV, Long GV. New RAS-mutant Pancreatic Adenocarcinoma with Combined BRAF and MEK inhibition for Metastatic Melanoma. Journal of Clinical Oncology 2015, 33 (11) e52-e56

Lee CK, Goldstein D, Gibbs E, Joensuu H, Zalcberg J, Verweij J, Casali PG , Maki R, Cioffi A, Mcarthur G, Lord SJ, Yip D, Y. Kanjanapan Y, Rutkowski P.Development and Validation of Prognostic Nomograms for Metastatic Gastrointestinal Stromal Tumor Treated with Imatinib. European Journal of Oncology 2015 51 (7) 852-860.

Kuo JC, Gorddard N, Stuart-Harris R. Renal failure requiring hemodialysis in two patients with metastatic breast cancer treated with everolimus. Breast Cancer Management 2015 4 (3) 129-134.

Kuo J, Craft P. Administration of chemotherapy in patients on dialysis. Anti-Cancer Drugs 2015. 26 (7) 779-84.

Parakh S, Wong H, Rai R, Ali S, Field K, Shapiro J, Wong R, Nott L, Gibbs P, D. Yip D. Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia Journal of Geriatric Oncology 2015, 6 (5):387-394

Day D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Andrews M, Davis ID, Azad A, Rosenthal M, Wong S, Arifeen S, Alam M, Gibbs P, Tran B. Patterns of Care for Metastatic Renal Cell Carcinoma in Australia. British Journal of Urology International 2015 116, S3, 36-41.

Kanjanapan Y, Prasanna T, Perampalam K, Yip D. The Challenge of Managing Adrenocortical Carcinoma: two case studies. International Journal of Endocrine Oncology 20152 (3), 175-184.

Nagrial AM, Chin VT, Sjoquist KM, Pajic M, Horvath LG, Biankin AV,Yip D. Second-Line treatment in inoperable pancreatic adenocarcinoma: An overview and synthesis of all clinical trials Critical Reviews of Hematology and Oncology 2015, 96,(3), 483-497.

Kuo JC, Gorddard N, Stuart-Harris R.Renal Failure Requiring Hemodialysis in Two Patients with Metastatic Breast Cancer Treated with Everolimus. Breast Cancer Manage 4: 129-134, 2015.

Kuo J, Hawkins C, Yip D. Application of hypersensitivity skin testing in chemotherapy-induced pneumonitis. Asia Pacific Allergy 2015,5 (4):234-6.

Shahnam A, Samarawickrema I, Ali A. Sun-protection practices among undergraduates at an Australian University. (2015) Australasian Journal of Dermatology, 58(2), 93-98

Garvey G, Thewes B, He V F Y, Davis E, Girgis A, Valery P C, Giam K, Hocking A, Jackson J, Jones V, Yip D. Indigenous cancer patient and staff attitudes towards unmet needs screening using SCNAT-IP (2016) Supportive Care in Cancer 24(1), 215-223

Boulding T, Wu F, McCuaig R, Dunn J, Sutton C R, Hardy K, Tu W, Bullman A, Yip D, Dahlstrom J E, Rao Sudha. Differential roles for DUSP family members in epithelial-to-mesenchymal transition and cancer stem cell regulation in breast cancer (2016) Public Library of Science one 11(2), e0148065

Garvey G, Thewes B, He V, Davis E, Girgis A, Valery P, Giam K, Hocking A, Jackson J, Jones V, Yip D. Indigenous cancer patient and staff attitudes towards unmet needs screening using the SCNAT-IP. Supportive Care in Cancer 2016, 24(1):215-23

Malik L, Chua Y, Butt NS, Yip D. Single institutional series of neuroendocrine tumours manage in the Australian Capital Territory. Asia Pacific Journal of Clinical Oncology 2016 12 (1): e133-e140.

Day D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Davis I D, Azad A A, Wong S, Rosenthal M, Gibbs P, Tran B. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma (2016) Internal Medicine Journal 46(11), 1291-1297

Thewes B, Davis E, Girgis A, Valery P C, Giam K, Hocking A, Jackson J, He V Y, Yip D, Garvey G.
Routine screening of indigenous cancer patients’ unmet support needs: a qualitative study of patient and clinician attitudes (2016) International Journal for Equity in Health 15(1), 90

Toohey K, Pumpa K L, Arnolda L, Cooke J, Yip D, Craft P S, Semple S. A pilot study examining the effects of low-volume high-intensity interval training and continuous low to moderate intensity training on quality of life, functional capacity and cardiovascular risk factors in cancer survivors (2016) PeerJ 4, 2613

Lee B, Wong H L, Tacey M, Tie J, Wong R, Lee M, Nott L, Shapiro J, Jennens R, Turner N, Tran B, Ananda S, Yip D, Richardson G, Parente P, Lim L, Stefanou G, Burge M, Iddawela M, Power J, Gibbs P. The Impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study (2016) Asia-Pacific Journal of Clinical Oncology

Kuo JC, De Silva M, Diwakarla C, Yip D. Improving the delivery of ambulatory care for cancer patients: experience of the Rapid Assessment Clinic in a tertiary institution Asia Pacific Journal of Clinical Oncology 2016,

Quek R, Farid M, Kanjanapan Y, Lim C, Tan I B, Kesavan S, Kiat T, Lim H, Oon L L E, Goh B K P, Chan W H, Teo M, Chung A Y F, Ong H S, Wong W K, Tan P, Yip D. Prognostic significance of KIT exon 11 deletion mutation in intermediate-risk gastrointestinal stromal tumor (2016) Asia-Pacific Journal of Clinical Oncology 

Wong H L, Lee B, Field K, Lomax A, Tacey M, Shapiro J, McKendrick J, Zimet A, Yip D, Nott L, Jennens R, Richardson G, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P. Impact of Primary Tumor Site of Bevacizumab Efficacy in Metastatic Colorectal Cancer (2016) Clinical Colorectal Cancer 15(2), 9-15

Bray V J, Dhillon H M, Bell M L, Kabourakis M, Fiero M H, Yip D, Boyle F, Price M A, Vardy J L. Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After Chemotherapy (2016) Journal of Clinical Oncology 35(2), 217-225

Nguyen BH, Kuo J, Budiman A, Christie H, Ali S. Two Cases of Clinical Myasthenia Gravis Associated With Pembrolizumab Use in Responding Melanoma Patients. (2017) Melanoma Research. 27(2), 152-154

Kuo J C, Silva M, Diwakarla C, Yip D. A Rapid Access Clinic to improve delivery of ambulatory care to cancer patients (2016) Asia-Pacific Journal of Clinical Oncology

Dhillon H M, Bray V J, Bell M L, Kabourakis M, Fiero M H, Yip D, Boyle F, Price M A, Vardy J L. A Randomised Controlled Trial (RCT) Evaluating a Web Based Cognitive Rehabilitation Programme (CRP) in Cancer Survivors Reporting Cognitive Symptoms Following Chemotherapy (2016) International Journal of Behavioral Medicine 23, 132-133

Beatty L, Kemp E, Turner J, Milne D, Yip D, McKinnon S, Katris P, Yaters P, Lambert S, Koczwara B. Who Uses, and How Do They Benefit From, Online Psychotherapuetic Interventions for Cancer-Related Distress? An Outcomes Analysis of ‘Finding My Way’ (2016) International Journal of Behavioral Medicine 23, 123-124

Lee B, Wong H L, Tacey M, Tie J, Wong R, Lee M, Nott L, Shapiro J, Jennens R, Turner N, Tran B, Ananda S, Yip D, Richardson G, Parente P, Lim L, Stefanou G, Burge M, Iddawela M, Power J, Gibbs P. The Impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study (2016) Asia-Pacific Journal of Clinical Oncology

Lok S W, Pellegrini L, Greenberg S, Oakman C, Green M, Foo S, Richardson G, Yip D, Nott L, Gibbs P, Boer R D. Tabitha – A Prospective Multi-site Registry Capturing Treatment and Outcome Data in the Metastatic Her2-postive Breast Cancer Patient (2016) Asia-Pacific Journal of Clinical Oncology 12, 60

Strach M C, Lee M, Lomax A J, Ng M, Guirrieri M, Prasanna T, Wong H L, Lee B, Mckendrick J, Lim L, Kosmider S, Tie J, Yip D, Nott L, Johns J, Harold M, Gibbs P, Wong R. Treatment Sequencing And Outcomes in Synchronous Metastatic Rectal Cancer (2016) Asia-Pacific Journal of Clinical Oncology 12, 60

Lee B, Wong H L, Tie J, Wong R, Lee M, Nott L M, Shapiro J D, Jennens R, Turner N H, Tran B, Ananda S, Yip D, Richardson G E, Parente P, Lim L, Stefanou G, Burge M E, Iddawela M Y, Gibbs P. Impact of anti-VEGF therapy in metastatic colorectal cancer with an intact primary tumour (2016) Journal of Clinical Oncology 34(4), 650

Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Wong R, Kosmider S, Tran B, Desai T, Hayes T M, Haydon A M, Yip D, Christie M, Strausberg R, Diaz L A, Papadopoulos N, Kinzler K W, Vogelstein B, Gibbs P. The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers (2016) Journal of Clinical Oncology 34, 2016

Barbour A, O’Rourke N, Chen H, Chua Y J, Kench J, Hicks R L, Samra J, Pavlakis N, Haghighi K S, Yip S, Donoghoe M, Friend C, Burge M E, Fawcett J, Harris M, Aghmesheh M, Joubert W L, Gebski V, Simes J, Goldstein D. Initial survival outcomes for the AGITG GAP study – a phase II study of perioperative nab-paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (2016) Journal of Clinical Oncology 34(15), 4105

Diwakarla, C, Pranavan, G & Gatenby, P. (2016). Hypogammaglobulinemia and Abiraterone Therapy for Metastatic Prostate Cancer. Targeted Oncology. Retrieved from http://www.targetedonc.com/publications/targeted-therapies-cancer/2016/2...

Beatty L, Kemp E, Binnion C, Turner J, Milne D, Butow P, Lambert S, Yates P, Yip D, Koczwara B. Uptake and adherence to an online intervention for cancer-related distress: older age is not a barrier to adherence but may be a barrier to uptake (2017) Supportive Care in Cancer 25, 1905

Au L, Turner N, Wong H, Field K, Lee B, Boadle D, Cooray P, Karikios D, Kosmider S, Lipton L, Nott L, Parente P, Tie J, Tran B, Wong R, Yip D, Shapiro J, Gibbs P. How accurate are medical oncologists’ impressions of management of metastatic colorectal cancer in Australia? (2017) Asia-Pacific Journal of Clinical Oncology

Brennan B, Hemmings CT, Clark I, Yip D, Fadia M, Taupin DR. Universal molecular screening does not effectively detect Lynch syndrome in clinical practice (2017) Therapeutic Advances in Gastroenterology 10 (4), 361-371

Squire T, Buchanan G, Rangiah D, Davis I, Yip D, Chua YJ, Rich T, Elsaleh H. Does chronomodulated radiotherapy improve pathological response in locally advanced rectal cancer? (2017) Chronobiology International 34, 492-503

Diwakarla C, Hannan K, Hein N, Yip D. Advanced pancreatic ductal adenocarcinoma-Complexities of treatment and emerging therapeutic options (2017). World Journal of Gastroenterology 23 (13), 2276

Strach MC, Lee M, Lomax A, Ng M, Guerrieri M, Prasanna T, Wong H, Lee B, Mckendrick JJ, Lim L, Kosmider S, Tie J, Yip D, Nott LM, Johns J, Harold M, Gibbs P, Wong R. Treatment sequencing and outcomes in synchronous metastatic rectal cancer (2017) Journal of Clinical Oncology

Lee B, Mendis S, Lee M, Wong R, Kosmider S, Shapiro JD, Yip D, Steel SA, Nott LM, Jennens R, Lipton LR, Burge ME, Ananda S, Gibbs P.  Left versus right sided colorectal cancer: Teasing out drivers of disparity in outcomes in metastatic disease (2017) Journal of Clinical Oncology 35(4), 682

Lee B, Anton A, Lee M, Wong R, Parente P, Shapiro J D, Yip D, Steel S A, Nott L M, Stefanou G, Iddawela M Y, Gibbs P, Tran B. Examining progression-free survival in first and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC) (2017) Journal of Clinical Oncology 35(4), 728

Prasanna T, Craft P, Balasingam G, Haxhimolla H, Pranavan G: Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity: Frontiers in Oncology (2017) (https://doi.org/10.3389/fonc.2017.00260)

Prasanna T, Briggs G, Jain S, Yip D. Massive fatal pulmonary haemorrhage during bevacizumab treatment following microwave ablation therapy for oligometastatic lung metastasis from rectal cancer. Interact CardioVasc Thorac Surg 2017; doi:10.1093/icvts/ivx342

Book Chapters

Penny R, Stuart-Harris R. Interferons: Therapeutic Uses. Encyclopedia of Life Sciences 2001. ISBN: 9780470015902 (Book)

Chua Y, Steer C, Yip D. Recent Advances in Small Cell Lung Cancer. In Carafaro RL (ed). Focus on Lung Cancer Research. Nova Science Publishers, NY 2004

Yip D, Gorddard N. Oncological Emergencies:Diagnosis and Management. In: Robotin M, Olver I, Girgis, A (Eds)When Cancer Crosses Disciplines: A Physician's Handbook. Imperial College Press, London, 2010.

Zalcberg J, Yip D, Hemmings C, Mann B, Blanke C. Gastrointestinal Stromal Tumors. In: Blanke C, Rodel C, Talamonti MS (Eds) Gastrointestinal Oncology: A Practical Guide. Springer-Verlag: Berlin Heidelberg 2011.

Tan TH, Lees J, Pranavan G, Yip D. New Systemic Approaches in the Treatment of Metastatic Renal Cell Carcinoma. In: Amato R (Ed) Emerging Research and Treatments in Renal Cell Carcinoma. p.369-406, InTech: Rijeka, 2012.

Christie, D, Yip, D, Cancer Council Australia Oncology Education Committee. Cancer of unknown primary [Version URL: wiki.cancer.org.au/oncologyformedicalstudents_mw/index.php?oldid=1429, cited 2014 Sep 21]. Available from wiki.cancer.org.au/oncologyformedicalstudents/Cancer_of_unknown_primary. In: Sabesan S, Olver I, editors. Clinical oncology for students. Sydney: Cancer Council Australia. Available from: wiki.cancer.org.au/oncologyformedicalstudents/Clinical_Oncology_for_Medical_Students.

High, H, Yip, D, Cancer Council Australia Oncology Education Committee. Cancer biology: Familial cancers and genetic testing [Version URL: wiki.cancer.org.au/oncologyformedicalstudents_mw/index.php?oldid=1414, cited 2014 Sep 21]. Available from wiki.cancer.org.au/oncologyformedicalstudents/Cancer_biology:_Familial_cancers_and_genetic_testing. In: Sabesan S, Olver I, editors. Clinical oncology for students. Sydney: Cancer Council Australia. Available from: wiki.cancer.org.au/oncologyformedicalstudents/Clinical_Oncology_for_Medical_Students

Lee, A, Elsaleh, H, Yip, D, Cancer Council Australia Oncology Education Committee. Colorectal cancer [Version URL: wiki.cancer.org.au/oncologyformedicalstudents_mw/index.php?oldid=1424, cited 2014 Sep 21]. Available from wiki.cancer.org.au/oncologyformedicalstudents/Colorectal_cancer. In: Sabesan S, Olver I, editors. Clinical oncology for students. Sydney: Cancer Council Australia. Available from: wiki.cancer.org.au/oncologyformedicalstudents/Clinical_Oncology_for_Medical_Students

Lee, A, Elsaleh, H, Yip, D, Cancer Council Australia Oncology Education Committee. Oesophageal cancer [Version URL: wiki.cancer.org.au/oncologyformedicalstudents_mw/index.php?oldid=1437, cited 2014 Dec 30]. Available from wiki.cancer.org.au/oncologyformedicalstudents/Oesophageal_cancer. In: Sabesan S, Olver I, editors. . Sydney: Cancer Council Australia. Available from: wiki.cancer.org.au/oncologyformedicalstudents/Clinical_Oncology_for_Medical_Students

Research presentations

Yip D, Karapetis CS, Strickland A, Lang G, Holford C, Harper PG. A Phase I trial of escalating dose eniluracil/oral 5-fluorouracil plus oxaliplatin (OXA) in patients with advanced gastrointestinal malignancies. Proc Clin Onc Soc Austr Annual Scientific Meeting 2000; Abstract142,(Presentation).

Yip D, Karapetis CS, Strickland A, Steer C, Holford C, Harper PG. A Phase I trial of escalating dose eniluracil/oral 5-fluorouracil plus oxaliplatin (OXA) in patients with advanced gastrointestinal malignancies. Proc Am Soc Clin Oncol 2001; Abstract 2079.

Donellan P, Strickland AH, Steer, Yip D, Ring A, Mason R, Owen W, Ellul F, Dussek R, Harper PG. Downstaging chemotherapy followed by surgery in the treatment of locally advanced oesophagogastric cancer. British Oesophagogastric Cancer Group Meeting, London, 2001 (Oral presentation)

Strickland A, Donellan P, Yip D, Steer C, Ring A, Marx G, Mason R, Harper P. Downstaging chemotherapy followed by surgery in the treatment of locally advanced oesophagogastric cancer. Medical Oncology Group of Australia Annual Scientific Meeting, Sunshine Coast, 2001 (Poster).

Hawkins CA, Yip D, Bowden F,Hurwitz M, Cook MC. Common variable immunodeficiency in an 88 year old woman. Proc Aust Soc Clin Immuno Allerg Annual Scientific Meeting 2001; (Presentation).

Karapetis CS, Steer C, Strickland AH, Yip D, Marx G, Yip S, Harper PG. A phase I/II study of epirubicin, cisplatin, high dose 24-hour infusion 5 fluorouracil and sodium folinate (ECSF) for advanced gastroesophageal carcinoma. Proc Am Soc Clin Oncol 2002; 21 A2245.

Gorddard N, Shadbolt B. Craft P. Describing the onset of weakness in patients with advanced cancer. Proc Am Soc Clin Oncol 2002; 21 A1500 (Poster).

Barresi J, Byrne D, Shadbolt B, Stuart-Harris R. The Canberra symptom scorecard: a tool to measure symptoms in patients with metastatic cancer. Proc Am Soc Clin Oncol 2002; 21 A994 (Presentation).

Hughes B, Nahar N, Chao M, Carroll S, Goldstein D, Yip D. An Audit of the toxicity of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma. Proc Medical Oncology Group National Conference, Canberra 2003 (Presentation)

Lim L, Gibbs P, Smith D, Yip D, Little A, Bailey W, Shapiro JD, Dowling R, Lichtenstein M. Prospective study of selective internal radiation therapy with intra-arterial infusion of yttrium 90 microspheres (Sirtex) for non-resectable primary or secondary hepatic malignancies. Proc Medical Oncology Group National Conference, Canberra 2003 (Poster and Presentation).

Gorddard N, Hughs B, May J, Yip D, Craft P, Leong D, Stuart-Harris R. A phase II study of vinorelbine and ifosphamide for previously untreated advanced non-small cell lung cancer. Proc Clinical Oncological Society of Australia, Perth 2003 (Poster).

Lim L, Gibbs P, Smith D, Yip D, Bailey W, Shapiro JD, Dowling R, Lichtenstein M, Little A. Prospective study of selective internal radiation therapy (SIR spheres) in patients with metastatic colorectal cancer previously treated with 5-fluorouracil. ASCO Gastrointestinal Symposium, San Francisco 2004 (Poster).

Cheong KA, Karapetis C, Chrystal KF, Yip D, Strickland A, Steer C, Harper P. A phase I/II study of epirubicin, cisplatin, high dose 24hour infusion 5 fluorouracil and sodium folinate (ECSF) for advanced gastroesophageal carcinoma. ASCO Gastrointestinal Symposium, San Francisco, 2004 (Abstract 69)

Hughes B, Nahar N, Yip D, Chao M, Carroll S, Goldstein D, Gibbs P, Burmeister B, Karapetis C. An Audit of the toxicity of postoperative chemoradiotherapy as adjuvant therapy for resected gastroesophageal adenocarcinoma: an Australian multicentre experience.15th International Congress on Anti-Cancer Treatment, Paris 2004 (Poster)

Grimpen, F, Yip D, McArthur G, Waring P, Goldstein D, Loughrey, Chong, G. Resistance to imatinib mesylate associated with absence of FDG-avidity on PET and acquired exon 17 mutation in gastrointestinal stromal tumour (GIST). Clinical Oncological Society of Australia Annual Scientific Meeting, Canberra 2004 (Presentation).

Yip D, Strangman D, McNally E,The Establishment of a Cancer Resources Centre and Carers Lounge. Clinical Oncological Society of Australia Annual Scientific Meeting, Canberra 2004 (Poster).

Lim L, Gibbs P, Smith D, Yip D, Dowling R, Lichtenstein M, Little A, Bailey W, Shapiro JD. Prospective study of selective internal radiation therapy (SIR spheres) in patients with metastatic colorectal cancer. Clinical Oncological Society of Australia Annual Scientific Meeting, Canberra 2004 (Poster).

Dahlstrom JE, Craft P, Zhang Y, Buckingham J, Jacob G, Tait N. Breast cancer and treatment in the Australian Capital Territory (ACT) and South Eastern New South Wales (SE NSW) Quality Assurance Project 1997-2002. Clinical Oncological Society of Australia Annual Scientific Meeting, Canberra 2004 (Poster).

Lewis C, Yip D, Zingarelli G. Anticipated Changes to Antiemetic Presecribing Practice in Chemotherapy Patients Involved in a Special Access Scheme for Aprepitant: A Neurokinin-1 (NK-1) Receptor Antagonist. Clinical Oncological Society of Australia Annual Scientific Meeting, Canberra 2004 (Poster).

Pranavan G, Northey J, Kuhnell C, Boland M, Yip D. The efficacy and tolerability of the Penguin Scalp Cooling System (SCS) for prevention of chemotherapy induced alopecia at The Canberra Hospital. Clinical Oncological Society of Australia Annual Scientific Meeting, Brisbane 2005 (Poster).

Davis AJ, Lewis CR, Moylan EJ, Parnis FX, Brew S, Ackland SP. A phase II multicenter study of combination chemotherapy with capecitabine (C) and intravenous (iv) vinorelbine (V) in patients (pts) with pretreated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2006; 24 A10665.

Gibbs, P, Tan T.H.,Yip, D, Kosmider S. Clinical Experience of Selective Internal Radiation Therapy in Combination with Systemic Chemotherapy as First-Line Therapy in Patients with Unresectable Hepatic Metastases from Colorectal Cancer. KL International Breast and Colorectal Cancer Congress, Kuala Lumpur, 2007.

Pranavan G, Gorddard N. Postoperative Chemoradiation for Glioblastoma Multiforme, a retrospective review. Medical Oncology Group Annual Scientific Meeting, Melbourne 2007 (Poster).

Pranavan G, Tan TH, Stuart-Harris R.Clinical Efficacy and Tolerability of Fulvestrant as Third Line Therapy of Metastatic Breast Cancer: A Retrospective Analysis. Proc Clinical Oncological Society of Australia Annual Scientific Meeting, 2007 (Poster).

Tan HT, Kosmider S, Yip D, Gibbs P. Clinical experience of Selective Internal Radiotherapy in combination with chemotherapy as first line therapy in patients with unresectable hepatic metastases from colorectal cancer.Clinical Oncological Society of Australia Annual Scientific Meeting, Adelaide 2007 (Poster).

Stuart-Harris R, Shadbolt B, Chaudri Ross HA. The prognostic significance of discordant receptor results and the progesterone receptor in metastatic breast cancer. Proc European Breast Cancer Conference, Berlin, 2008.

O'Callaghan CJ, Tu D, Karapetis CS, Au HJ, Moore MJ, Zalcberg JR, Trudeau M, Yip D, Vachan B, D Jonker DJ. The relationship between the development of rash and clinical and quality of life outcomes in colorectal cancer patients treated with cetuximab in NCIC CTG CO.17.Proc Am Soc Clin Oncol 2008;26 A4130(Poster).

Tan HT, Kosmider S, Yip D, Gibbs P. Clinical experience of Selective Internal Radiotherapy in combination with chemotherapy as first line therapy in patients with unresectable hepatic metastases from colorectal cancer.Proc Am Soc Clin Oncol, 2008;26, A15080.

Hoy J, Neeman T, Stuart-Harris R, Davis A. Risk of venous thromboembolism in patients receiving FEC chemotherapy for early breast cancer. Clinical Oncological Society of Australia Annual Scientific Meeting 2008(Poster).

Parker S, Skeels A, Yip D. Chemotherapy usage in breast, colorectal cancer and lung cancer patients referred to palliative care in the last months of life. Clinical Oncological Society of Australia Annual Scientific Meeting, Sydney 2008 (Poster)

Tebbutt NC, Gebski V, Wilson K, Cummins M, Chua Y, Robinson B, Broad A, Cunningham D, Simes J, Price T. International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial. Proc Am Soc Clin Oncol 2009 27: 4023 (Poster)

Craft PS, Buckingham J, Dahlstrom JE, Beckmann K,Zhang Y, Stuart-Harris R, Jacob G, Roder D, Tait N.Variations in care for operable breast cancer and outcomes between rural and metropolitan centers in Australia.Proc Am Soc Clin Oncol 2009;abstr e11517

Shah B, Kleiven H, Yip D, Gorddard N. Patient-initiated Outpatient Management of Low-risk Febrile Neutropenia. Medical Oncology Group Annual Scientific Meeting, Canberra, 2009 (Poster).

Shah B, Kleiven H, Yip D, Gorddard N. Patient-initiated Outpatient Management of Low-risk Febrile Neutropenia. Clinical Oncological Society of Australia Annual Scientific Meeting, Gold Coast, 2009 (Poster).

Krishnamoorthy Yip D. Bisphosphonate usage in oncology patients and its relationship to osteonecrosis of the jaw: an audit of treatment in an oncology unit. Clinical Oncological Society of Australia Annual Scientific Meeting, Gold Coast, 2009 (Poster).

Goldstein D,Lee C,Hui Y,Shah B,Yip D,McArthur GA. Development of a nomogram to predict overall survival in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first-line treatment with imatinib.Proc Am Soc Clin Oncol, 2010 28:7s (Poster).

Kosmider S, Yip D, Tan H, Dowling R, Lichtenstien M, Gibbs P. Selective internal radiation therapy combined with systemic chemotherapy as a first-line treatment for unresectable liver-dominant colorectal cancer. World Congress on Gastrointestinal Cancer, Barcelona Ann Oncol (2010) 21(suppl 6): vi67 (Poster).

Joshi S, Steer CB, Yoong J, Lakhanpal R, Kirsop S, Dunlop T, Mileshkin L, Yip D, Marx GM, Hovey EJ, Della Fiorentina S, Venkateswaran L, Lethborg C, Tattersall Liew MS, Ansell K, Field K, Singal N, Goldstein D. Geriatric assessment (GA) of older patients with cancer in Australia – a multicentre audit. Clinical Oncological Society of Australia Annual Scientific Meeting, Melbourne 2010 (Poster)

Behm C, Li JR, Zhang Y, Dahlstrom JE, Craft PS, Buckingham JM, Rezo A, Stuart-Harris R, Cho C. Female breast cancer in the Australian Capital Territory (ACT): A review of new research. Royal Australasian College of Pathologists, Annual Scientific Meeting, 2011.

Cooper A, Tejani N, Rezo, A, Yip D. Numb Chin Syndrome: A case series of a potentially overlooked but important clinical syndrome associated with malignancy. Clinical Oncological Society of Australia Annual Scientific Meeting, Perth 2011 Abstract 202 (Poster)

Tazbirkova A, Allen R, Kosmider S, Gibbs P, Yip D. Serious hepatic complications of radioactive yttrium microspheres (SIR-Sphere) embolisation of liver tumours. Clinical Oncological Society of Australia Annual Scientific Meeting, Perth 2011 Abstract 216 (Poster).

Butow PN, Phillips F, White K, Underhill C, Grimison P, Yip D, Goldstein D. Improving the Cancer Journey in Rural and Regional Australia. Clinical Oncological Society of Australia Annual Scientific Meeting, Perth 2011 Abstract 387.

Rapke T, De Souza P, Marx G, Parente P, Hill A, Bonaventura A, Michele T, Craft P, Abdi E, Lloyd A Modafinil for fatigue associated with docetaxel-based chemotherapy: a randomized controlled trial. American Society of Clinical Oncology Genitourinary Meeting, 2012.

Chua Y, Karapetis C, Underhill C, Nott L, Goldstein D, Cronk M, Gebski V, Wong N, Sjoquist K, Biankin A. PAN1: a randomized phase II study evaluating potential predictive biomarkers in the treatment of metastatic pancreatic cancer. Proceedings of the American Society of Clinical Oncology Annual Meeting, 2012 Chicago. (Abstract TPS4137)

Malik L, Chua YJ, Butt N, Yip D. Single institutional series of neuroendocrine tumours managed in the Australian Capital Territory. European Neuroendocrine Tumor Society Annual Conference Conference, Copenhagen, 2012.

Ransom D, Wilson D, Bishnoi SK, Simes J, Yip D, Christos Stelios Karapetis CS, Gebski V, Gordon S, Fournier M, Ferry DR, Abbas H, Midgley RA, Price TJ. Results of Australasian Gastrointestinal Trials Group (AGITG) Arctic study: An international audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines (FP). Proceedings of the American Society of Clinical Oncology 2012 (Abstract 13007)

Malik L, Chua YJ, Butt N, Yip D. Single institutional series of neuroendocrine tumours managed in the Australian capital territory. Proceedings of the American Society of Clinical Oncology 2012 (Abstract 14703)

Hovey E, De Souza PL, Marx GM, Rapke T, Parente P, Hill A, Bonventura A Michele A, Craft PS, Ehtesham A, Lloyd AR. Modafinil for fatigue associated with docetaxel-based chemotherapy: a randomized controlled trial. Proceedings of the American Society of Clinical Oncology 2012 (Abstract 15152)

Field K, Kosmider S, McKendrick J, Yip D, Parakh S, Burge M, Moore K, Shapiro J, Nott L, Wuttke M, Parente P, Bae S, Gibbs P. Prescribing patterns for bevacizumab in first-line metastatic colorectal cancer: Exploring the introduction of a new drug into routine clinical practice. Medical Oncology Group of Australia Annual Scientific Meeting, Brisbane 2012 (Poster).

Field K, Shapiro J, Yip D, Otty Z, Burge M, Sharma A, Lim L, Lipton L, Stefanou G, Desai J, Tie J, Gibbs P Patterns of care according to treatment intent for metastatic colorectal cancer (mCRC): A review of routine practice. Medical Oncology Group of Australia Annual Scientific Meeting, Brisbane 2012 (Poster).

Parakh S, Gananahda S, Allen R, Yip D. Cholecystitis as a complication of hepatic implantation of radioactive yttrium resin microspheres for metastatic cancer. Medical Oncology Group of Australia Annual Scientific Meeting, Brisbane 2012 (Poster).

Yip D, Bean EG, Rezo A, Cho C, Zhang Y, Twin J, Carpenter JE, Dahlstrom JE. Breast Cancer Tissue Banking Project in the Australian Capital Territory
Canberra Health Annual Research Meeting 2012 (Poster).

Parakh S, Gananahda S, Allen R, Yip D. Cholecystitis as a complication of hepatic implantation of radioactive yttrium resin microspheres for metastatic cancer. Canberra Health Annual Research Meeting 2012 (Poster).

Yip D, Parakh S, Hemmings C, Kosmider S Filling the knowledge void-the BioGrid facilitated solution. Canberra Health Annual Research Meeting 2012 (Poster).

Price T, Wilson K, Simes J, Yip D, Tebbutt N, Karapetis C, Gebski V, Fournier M, Ferry D, Ransom D. Final results of Australasian Gastro-Intestinal Trials Group (AGITG) ARCTIC Study – An international audit of raltitrexed for patients with cardiac toxicity (CT) induced by Fluoropyrimidines (FP). European Society of Medical Oncology Congress Vienna, 2012.

Ransom D, Wilson K, Simes J, Yip D, Tebbutt N, Karepetic C, Fournier M, Ferry D. Price T. Final results of Australasian Gastrointestinal Trials Group (AGITG) ARTIC Study-An international audit of raltitrexed for patients with cardiac toxicity (CT) induced by fluropyrimidines (FP). Clinical Oncological Society of Australia Annual Scientific Meeting, Brisbane 2012 (Poster)

Vien T, Yip D. A retrospective clinical audit comparing neuropathy associated with two different schedules of oxaliplatin in the treatment of metastastic colorectal carcinoma. Clinical Oncological Society of Australia Annual Scientific Meeting, Brisbane 2012 (Poster)

Wong HL, Field KM, Tie J, Kosmider S, Shapiro JD, McKendrick JJ, Parente P, Lipton LR, Yip D, Parakh S, Nott LM, Gibbs P. Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status? (Poster) Gastrointestinal Cancers Symposium J Clin Oncol 30: 2012 (suppl 34; abstr 534)

Field KM, McKendrick JJ, Shapiro JD, Tie J, Bae S, Burge ME, Yip D, Nott LM, Gibbs P. First-line clinical trials and metastatic colorectal cancer: How selected are clinical trial participants? (Poster) Gastrointestinal Cancers Symposium J Clin Oncol 30: 2012 (suppl 34; abstr 524).

Field KM, Shapiro JD, McKendrick JJ, Hui-Li Wong HL, Desai J, Lipton LR, Suzanne Kosmider, Nott LM, Stefanou G, Parente P, Zimet AS, Lim L, Jennens R, Yip D, Burge ME, Gibbs P. Metastatic colorectal cancer and management in public versus private hospitals: Similarities and differences. (Poster) Gastrointestinal Cancers Symposium J Clin Oncol 30: 2012 (suppl 34; abstr 497).

Lakhanpal R, Stuart-Harris R, Chan A Kotasek D, Beith JM, Cuff K, Bastick PA, Lee CI. A multicenter audit of the incidence of febrile neutropenia and neutropenia associated with docetaxel and cyclophosphamide (TC) chemotherapy for early breast cancer. Proceedings of the American Society of Clinical Oncology 2013 (abstr 1079)(Poster)

Parakh S, Ali S, Wong HL, Field KM, Shapiro JD,Nott LM, McKendrick JJ, Gibbs P, Yip D. Patterns of care of elderly patients with metastatic colorectal cancer. Proceedings of the American Society of Clinical Oncology 2013 (abstr e14640).

Wong HL, Field KM, Tie J, Kosmider S, Shapiro JD, McKendrick J, Parente P, Lipton LR,Yip D, Parakh S, Nott LM, Gibbs P. Is there a role for chemotherapy in metastatic colorectal cancer patients with a poor performance status? Proceedings of the American Society of Clinical Oncology 2013 (abstr e14583).

Brule SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. Proceedings of the American Society of Clinical Oncology 2013 (abstr 3528)(Poster)

Parakh S, Ali S, Wong HL, Field KM, Shapiro JD,Nott LM, McKendrick JJ,Gibbs P, Yip D. Patterns of care of elderly patients with metastatic colorectal cancer. Canberra Health Annual Research Meeting 2013 (Poster).

Kuo J, Hawkins C, Yip D. Protocol and treatment outcome of rapid desensitization of chemotherapeutic agents in the Capital Region Cancer Service. Canberra Health Annual Research Meeting 2013 (Oral presentation).

Brule SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalcberg JR, Tu D, Goodwin RA. Location of colon cancer (rightsided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. Canadian Cancer Research Conference 2013 (Poster).

Kuo J, Hawkins C, Yip D. Treatment outcomes of rapid desensitisation of chemotherapeutic agents and monoclonal antibodies following hypersensitivity reactions. Clinical Oncology Society of Australia Annual Scientific Meeting, Adelaide 2013 (Oral presentation).

Parakh S, Ali S, Wong HL, Field KM, Shapiro JD,Nott LM, McKendrick JJ, Gibbs P, Yip D. Patterns of care of elderly patients with metastatic colorectal cancer. Clinical Oncology Society of Australia Annual Scientific Meeting, Adelaide 2013 (Oral presentation).

Mizrahi D, Naumann F, Broderick C, Yip D, Davis A, Samara J, Ryan M, Friedlander M. Physical activity (PA) participating for women with ovarian cancer. Clinical Oncology Society of Australia Annual Scientific Meeting, Adelaide 2013 (Poster presentation).

Curry G, Kuo J, Pranavan G, Yip D. Incidence of gastrointestinal toxicity with capecitabine monotherapy in metastatic breast and metastatic colorectal cancer patients. Clinical Oncology Society of Australia Annual Scientific Meeting, Adelaide 2013 (Poster presentation).

Kanjanapan Y, Chei-Hussein M, Hemmings C, Yip D. Retrospective analysis of resected gastrointestinal stromal tumours (GISTs) comparing existing risk stratification models and assessing the influence of GIST genotypes on recurrence and mortality. Clinical Oncology Society of Australia Annual Scientific Meeting, Adelaide 2013 (Poster presentation).

Lee CK, Joensuu H, McArthur G, Montemurro M, Yip D, Goldstein D, Bylina E, Andrzejuk J, Siedlecki JA, Rutkowski P. Development and validation of prognostic nomograms to predict survival outcomes in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first line imatinib therapy. Connective Tissue Oncology Society 18th Annual Meeting; 30 Oct–2 Nov 2013; New York.

Roohullah A, Hui-li Wong HL, Sjoquist K, Field K, Tran B, Shapiro J, McKendrick J, Yip D, Nott L, Gibbs P, Chantrill L. Safety and efficacy of bevacizumab and systemic therapy in metastatic colorectal cancer patients with peritoneal disease in the TRACC database. Gastrointestinal Cancers Symposium 2014 (abstract 595) (poster presentation).

Chua YJ, Karapetis CS, Gebski V, O’Connell R, Begbie S, Nott LM, Cronk MF, Underhill C, Abdi EA, Van Hagen T, Wong N, Hall M, Ferraro DA, Sjoquist KM, Santos C, Mackey JR, Goldstein D. Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil and leucovorin) treated patients with metastatic pancreatic cancer: the randomized phase II PAN1 study. Gastrointestinal Cancers Symposium; 2014.

Nagrial AM, Chin VT, Sjoquist K, Chantrill LA, Yip D. Survival benefit of second-line chemotherapy in advanced pancreatic adocarcinoma: A systematic review of the literature. Gastrointestinal Cancers Symposium 2014 (abstract 296) (poster presentation)

Lomax A, Wong HL, Field KM, Harold M, Shapiro JD, McKendrick JJ, Zimet AS, Yip D, Nott LM, Jennens R, Richardson GE, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P. Prognostic impact of clinicopathologic features in metastatic rectal versus colon cancer. Proceedings of the American Society of Clinical Oncology 2014 (e14518).

Wong HL, Field KM, Lomax A, Tacey M, David Shapiro JD, McKendrick JJ, Zimet AS, Yip D, Nott LM, Jennens R, Richardson GE, Tie J, Kosmider S, Parente P, LLim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P. Impact of tumor site on bevacizumab (BEV) efficacy in metastatic colorectal cancer (mCRC) Proceedings of the American Society of Clinical Oncology 2014 (e14558).

Wong HL, Field KM, Shapiro JD, McKendrick JJ, Zimet AS, Yip D, Nott LM, Jennens R, Richardson GE, Lipton LR, Stefanou G, Tie J, Kosmider S, Parente P, Wong R, Lim L, Cooray P, Tran B, Desai J, Gibbs P. Point-of-care capture of clinical interventions for metastatic colorectal cancer (mCRC) to develop and validate novel markers of the quality of cancer care. Proceedings of the American Society of Clinical Oncology 2014 (e17637).

Tie J, Kinde I, Wang Y, Wong HL, Skinner I, Wong R, Steel M, Diaz LA, Papadopoulos N, Kosmider S, Yip D, Underhill C, Haydon AM, Christie M, Strausberg R, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC). Proceedings of the American Society of Clinical Oncology 2014 (abstract 11015) (poster presentation).

Chin VT, Nagrial A, Chantrill LA, Sjoquist KM, O'Connor C, Pajic M, ABiankin AV, Yip D. Targeted therapies in the treatment of advanced pancreatic adenocarcinoma (PC): A systematic review and meta-analysis of randomized trials. Proceedings of the American Society of Clinical Oncology 2014 (abstract 15209).

Kanjanapan Y, Dai D, Kwan E, Lawrentschuk N, Andrews M, Davis I, Azad A, Rosenthal M, Wong S, Arifeen S, Alam M, Gibbs P, Tran B, Yip D. Sunitinib therapy for metastatic renal cell carcinoma (mRCC) in elderly patients (age 70 and over): a multi-institutional Australian experience. Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Annual Scientific Meeting, Melbourne 2014 (Poster presentation).

Dai D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Andrews M, Davis I, Azad A, Rosenthal M, Wong S, Arifeen S, Alam M, Gibbs P,Tran B. Real world data regarding patterns of care in Australian patients with metastatic renal cell carcinoma (mRCC). Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group Annual Scientific Meeting, Melbourne 2014 (Poster presentation).

Chin V, Nagrial A, Chantrill L, Sjoquist K, O’Connor C, Pajic M, Biankin A, Yip D. Pharmacologic interventions for advanced pancreatic cancer (PC) – a meta-analysis comparing gemcitabine alone (G) versus gemcitabine combinations (GCS). Medical Oncology Group of Australia Annual Scientific Meeting 2014 (oral presention).

Lomax A, Wong HL, Field KM, Harold M, Shapiro JD, McKendrick JJ, Zimet AS, Yip D, Nott LM, Jennens R, Richardson GE, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P. Prognostic impact of clinicopathological features in metastatic rectal vs colon cancer. Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (oral presentation).

Kuo J, Malik L, Mejia A, Yip D. Compliance with international guidelines and readability of informed consent forms for cancer clinical trials. Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (poster presentation).

Sardjono C, Bower J, McCloud P, Mainwaring P, Sewak S, Wong S, Kotasek D, Lee SH, Chung JS, Sanmugarajah J, Troon S, Yip D, Singh N, Crump D, De Souza P.
A Phase II study of sequential therapy with pazopanib followed by everolimus in metastatic renal cell cancer – Study Update. Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (poster presentation).

Wong H, Field K, Lomax A, Tacey M, Shapiro J, McKendrick J, Zimet A, D Yip D, Nott L, Jennens R, Richardson G, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P. Impact of tumour site on bevacizumab efficacy in metastatic colorectal cancer (mCRC). Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (oral presentation).

Kanjanapan Y, Yip D, Dahlstrom J, Craft P. Benefit of adjuvant trastuzumab with chemotherapy (ATWC) in T1N0 HER2 positive breast cancer- interim results. Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (poster presentation).

Au L, Turner N, Wong H, Field K, Harold M, Boadle D, Cooray P, Karikios D, Kosmider S, Lipton L, Nott L, Parente P, Tie J, Tran B, Wong R, Yip D, Shapiro J, P Gibbs. How accurate are medical oncologists’ impressions of the management of patients with metastatic colorectal cancer (mCRC) in Australia? Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (poster presentation).

Turner N. Wong HL, Field KM, Shapiro JD, McKendrick JJ, Zimet AS, Yip D, Nott LM, Jennens R, Richardson GE, Lipton LR, Stefanou G, Tie J, Kosmider S, Parente P, Wong R, Lim L, Cooray P, Tran B, Desai J, Gibbs P. Point-of-care capture of clinical interventions for metastatic colorectal cancer (mCRC) to develop and validate novel markers of the quality of cancer care. Medical Oncology Group of Australian Annual Scientific Meeting, Sydney 2014 (poster presentation).

Kanjanapan Y, Yip D, Dahlstrom J, Craft P. Benefit of adjuvant trastuzumab with chemotherapy (ATWC) in T1N0 HER2 positive breast cancer- interim results. Canberra Health Annual Research Meeting, Canberra 2014 (oral presentation).

Kanjanapan Y, Dai D, Kwan E, Lawrentschuk N, Andrews M, Davis I, Azad A, Rosenthal M, Wong S, Arifeen S, Alam M, Gibbs P, Tran B, Yip D. Sunitinib therapy for metastatic renal cell carcinoma (mRCC) in elderly patients (age 70 and over): a multi-institutional Australian experience. Canberra Health Annual Research Meeting, Canberra 2014 (poster presentation)

Kuo J, Malik L, Mejia A, Yip D. Compliance with international guidelines and readability of informed consent forms for cancer clinical trials. Canberra Health Annual Research Meeting, Canberra 2014 (poster presentation).

Turner NH, Wong HL, Lee M, Aung SY, Rai R, Nott L, Yip D, Field K ,Shapiro J, Kosmider S, Wong R, Lipton L, Power J, Zimet A, Gibbs P. Association between diabetes mellitus (DM) and clinical outcomes in patients with metastatic colorectal cancer (mCRC). Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane, 2014 (poster presentation).

Tie J, Kinde I, Wang Y, Wong HL, Skinner I, Wong R, Steel M, Diaz LA, Papadopoulos N, Kosmider S, Yip D, Underhill C, Haydon AM, Christie M, Strausberg R, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA (ctDNA) as a marker of recurrence risk in stage II colon cancer (CC). Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane 2014 (poster presentation).

Aung SY, Turner N, Wong HL, Maddison C, Lee M, Rai R, Yip D, Field L, Shapiro J, Tie J, Tran B, McKendrick J, Richardson G, Desai J, Gibbs P, Nott L. Clinical Presentation, Treatment, and Outcomes of Colorectal Cancer Patients with Isolated Distant Lymph Node Metastases in Australia. Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane 2014 (poster presentation).

Turner N, Wong HL, Field L, Wong R, Shapiro J, Yip D, Nott L, Tie J, Kosmider S, Tran B, Desai J, McKendrick J, Zimet A, Richardson G, Iddawela M, Gibbs P. Defining and measuring variation in quality of care delivered to patient with metastatic colorectal cancer in routine practice. Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane 2014 (poster presentation).

Au L, Turner N, Wong HL, Field K, Harold M, Boadle D, Cooray P, Karikios D, Kosmider S, Lipton L, Nott L, Parente P, Tie J, Tran B, Wong R, Yip D, Shapiro J, Gibbs P. How accurate are medical oncologists’ impressions of the management of patients with metastatic colorectal cancer (mCRC) in Australia? Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane 2014 (poster presentation).

Lee M, Wong HL, Turner N, Aung SY, Rai R, Maddison C, Nott L, Yip D, Field K, Shapiro J, Tie J, Tran B, McKendrick, Ananda S, Stefenou G, Jennens R, Gibbs P. Presentation, treatment and outcomes of young patients with metastatic colorectal cancer in Australia. Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane 2014 (poster presentation).

Lomax A, Wong HL, Field K, Harold M, Shapiro J, McKendrick J, Zimmet A, Yip D, Nott L, Jennens R, Richardson G, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Gibbs P. Prognostic impact of clinicopathological features in metastatic rectal vs colon cancer. Australian Gastro-Intestinal Trials Group Annual Scientific Meeting, Brisbane 2014 (poster presentation).

Garvey G, Thewes B,He V, Davies E, Girgis A, Valery P, Giam L, Hocking A, Jackson J, Jones V, Yip D. Patient and Clinician Perceptions of the Feasiblity of Utility of Routine Unmet Needs Screening for Indigenous Australians with Cancer, World Congress of Psycho-Oncology and Psychosocial Academy, Lisbon 2014 (poster presentation).

Wong H, Field K, Lomax A, Tacey M, Shapiro J, McKendrick J, Zimet A, D Yip D, Nott L, Jennens R, Richardson G, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P. Impact of tumour site on bevacizumab efficacy in metastatic colorectal cancer (mCRC). European Society of Medical Oncology Congress, Madrid 2014 (abstract 7170)(poster presentation).

Kuo JC,De Silva M,Yip D.Improving delivery of ambulatory care for cancer patients: experience of the Rapid Assessment Clinic in a tertiary institution. Clinical Oncology Society of Australia Annual Scientific Meeting,Melbourne, 2014 (poster presentation.

Kanjanapan Y, Segelov E. Learning through clinical trials:2013 and 2014 Preceptorship in Colorectal Cancer (CRC)-an initiative of the Australasian Gastrointestinal Trials Group(AGITG). Clinical Oncology Society of Australia Annual Scientific Meeting, Melbourne 2014 (poster presentation).

Kuo J, Malik L, Mejia A, Yip D. Compliance with international guidelines and readability of informed consent forms for cancer clinical trials.Clinical Oncology Society of Australia Annual Scientific Meeting, Melbourne 2014 (poster presentation).

Beatty L, Kemp E, Wade T, Katris P, Turner J, Yates P, Yip D, Wooten A, Lambert S, Butow P Koczwara B. Finding My Way:Preliminary findings from a RCT evaluating an internet self-help program for cancer related distress. Clinical Oncology Society of Australia Annual Scientific Meeting, Melbourne 2014 (oral presentation). 

Craft P, Epping Y, Zhang Y, for the ACT and SE NSW Breast Cancer Treatment Group.  A 15 year longitudinal study of breast cancer outcomes in a region. Clinical Oncological Society of Australia, Annual Scientific Meeting, Melbourne, Abstract 258, 2014.

Kuo JCraft P. Administration of chemotherapy in patients on dialysis. Clinical Oncological Society of Australia Annual Scientific Meeting, Melbourne Abstract 384. 2014.

Nagrial A, Chin VT, O'Connor C, Sjoquist KM, Chantrill LA, Biankin AV, Yip D. Role of chemoradiation in locally advanced pancreatic cancer: A systematic review and meta-analysis. Gastrointestinal Cancers Symposium, San Francisco 2015 (poster presentation).

Barbour A, O’Rourke N, Samra JS, Haghighi KS, Kench J, Mitchell J, Pavlakis N, Burge ME, Fawcett J, Gananadha S, Harris M, Aghmesheh M, Chua YJ, Joubert WL, Chan MMK, Chandrasegaram MD, Yip S, Simes J, Gebski V, Goldstein D. A multicenter, phase II trial of preoperative gemcitabine and nab-paclitaxel for resectable pancreas cancer: the AGITG GAP study. Gastrointestinal Cancers Symposium; 2015; San Francisco.

Dai D, Kanjanapan Y, Kwan EM, Yip D, Lawrentschuk N, Davis ID, Azad A, Rosenthal M, Arifeen U, Alam M, Gibbs P, Tran B. Can neutrophil-to-lymphocyte ratio be used to identify patients with metastatic renal cell carcinoma who may gain greater benefit from cytoreductive nephrectomy? Genitourinary Cancers Symposium, Orlando 2015 (poster presentation).

Larkin D, Nutt M, Ashmore T, Yip D, Rezo A, Currie M.  What matters to me? Consumer engagement to inform a survivorship model of care in the ACT. Survivorship Conference, Flinders Centre for Innovation in Cancer, Adelaide, 2015 (poster presentation).

Toohey K, Pumpa K, Cooke J, Arnolda L, Yip D, Craft P, Semple S. Effects of High vs Moderate Intensity Exercise on Functional Fitness and Quality of Life in Cancer Survivors: A Pilot Study. American College of Sports Medicine Annual Meeting, San Diego 2015 (poster presentation).

Turner NH, Wong HL, Lee M, Aung SY, Rai R, Maddison C, Nott LM, Yip D, Morris K, Field KM, Shapiro JD, Kosmider S, Wong R, Lipton LR, Power JD, Bae S, Zimet AS, Gibbs P. Association between type 2 diabetes mellitus (T2DM), diabetic therapies and clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC). American Society of Clinical Oncology Annual Meeting, Chicago 2015 (abstract e14637).

Lee M, Turner NH, Wong HL, Aung SY, Rai R, Maddison C, Morris K, Nott LM, Yip D, Field KM, Shapiro JD, Tie J, Tran B, Wong R, Ananda S, Stefanou G, Jennens R, Gibbs P; Clinicopathological characteristics and outcomes of young patients (YP) with metastatic colorectal cancer (mCRC) in Australia. American Society of Clinical Oncology Annual Meeting Chicago 2015 (abstract e14648).

Kanjanapan Y, Thomas SN, Yip D, Dahlstrom JE, Pathmanathan N, Craft PS; Effects of adjuvant trastuzumab with chemotherapy (ATWC) in T1N0 HER2 positive (HER2+) breast cancer. American Society of Clinical Oncology Annual MeetingChicago 2015 (abstract e11595).

Bray VJ, Dhillon HM, Bell M, Kabourakis M, Rice H, Yip D, Boyle FM, Price M, Vardy JL; Evaluation of a web-based cognitive rehabilitation programme (CRP) in cancer survivors reporting cognitive symptoms following chemotherapy. American Society of Clinical Oncology Annual Meeting Chicago 2015 (abstract 9510) (Oral presentation). Shahnam H, Tejani N, O’Brien E, Neeman T,  Ali  S. Utility of commonly available clinical parameters for predicting concurrent chemoradiotherapy toxicity following treatment of stage III non-small cell lung cancer. Canberra Health Annual Research Meeting, Canberra 2015 (oral presentation)

Kuo J, Hawkins C, Yip D. Application of skin testings for drug induced pneumonitis related to chemotherapeutic agents. Medical Oncology Group of Australia Annual Scientific Meeting (poster) Hobart 2015.

Sahadudheen K, Chua YJ, Yip D.  Clinical experience of gemcitabine and nab-paclitaxel treatment for advanced pancreatic cancer in the Australian Capital Territory. Medical Oncology Group of Australia Annual Scientific Meeting(poster) Hobart 2015.

Lee M, Turner N,Wong HL, Aung SY, Rai R, Maddison C, Morris K, Nott L, Yip D, Kathryn K, Shapiro J,  Tie J,Tran B, Wong R, Ananda S, Stefanou G, Jennens R,  Gibbs P. Clinicopathological Characteristics and Outcomes of Young Patients (YP) with Metastatic Colorectal Cancer (mCRC) in Australia. Medical Oncology Group of Australia Annual Scientific Meeting(poster) Hobart 2015.

Shahnam H, Tejani N, O’Brien E, Neeman T,  Ali  S. Utility of commonly available clinical parameters for predicting concurrent chemoradiotherapy toxicity following treatment of stage III non-small cell lung cancer. Medical Oncology Group of Australia Annual Scientific Meeting Hobart 2015 (poster presention).

Shahnam A, Samarawickrema I, Ali A. Sun-protection practices among undergraduates at an Australian University.  Medical Oncology Group of Australia Annual Scientific Meeting Hobart 2015 (Poster presentation).

Bray VJ, Dhillon HM, Bell M, Kabourakis M, Rice H, Yip D, Boyle FM, Price M, Vardy JL; Evaluation of a web-based cognitive rehabilitation programme (CRP) in cancer survivors reporting cognitive symptoms following chemotherapy. Medical Oncology Group of Australia Annual Scientific Hobart 2015 (Oral presentation).

Shahnam H, Tejani N, O’Brien E, Neeman T,  Ali  S. Utility of commonly available clinical parameters for predicting concurrent chemoradiotherapy toxicity following treatment of stage III non-small cell lung cancer. Clinical Oncological Society of Australia Annual Scientific Meeting, Hobart 2015 (Poster presentation)

Shahnam H, Tejani N, O’Brien E, Neeman T,  Ali  S. Utility of commonly available clinical parameters for predicting concurrent chemoradiotherapy toxicity following treatment of stage III non-small cell lung cancer. Clinical Oncological Society of Australia Annual Scientific Meeting, Hobart 2015 (Poster presentation)

De Silva M, Kuo J, Diwakarla, Yip D. A snapshot review of the impact of a Rapid Assessment Clinic on the care pattern of febrile neutropenia. Clinical Oncological Society of Australia Annual Scientific Meeting, Hobart 2015 (Poster presentation).

Kuo J, Hawkins C, Yip D. Application of skin testing for drug induced pneumonitis related to chemotherapeutic agents. Clinical Oncological Society of Australia Annual Scientific Meeting Hobart 2015 (Poster presentation).

Price T, Pavlakis N, Karapetis C, Michael M, Singhal N, Goldstein D,Van Hazel G, Zalcberg J, Hicks R, Yeend S, Chua YJ. The Clinical Oncology Society of Australia (COSA) SIGNETURe Neuroendocrine Tumor (NET) Registry of Australia: First Report of Patient Characteristics and Patterns of Care. European Neuroendocrine Tumor Society Conference, Barcelona 2015

Lee B, Wong HL, Tie J, Wong R, Lee M, Nott LM, Shapiro JD, Jennens R, Turner NH, Tran B, Ananda S, Yip D, Richardson GE, Parente P, Lim L, Stefanou G, Burge M, Iddawela MY, Gibbs P. Impact of anti-VEGF therapy in metastatic colorectal cancer with an intact primary tumour.GI Cancer Symposium, 2016 J Clin Oncol 34, (suppl 4S; abstr 650) (Poster presentation)

Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Wong R, Kosmider S, Tran B, Desai J, Hayes TM, Haydon AM, Yip D, Christie M, Strausberg R, Diaz LA, Papadopoulos N,  Kinzler KW, Vogelstein B, Gibbs P. The Potential of circulating tumor DNA (ct DNA ) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers. American Society of Clinical Oncology Annual Meeting, Chicago 2016, (abstract 351) (Oral presentation)

Barbour A, O'Rourke N, Chan H, Chua YJ, Kench J, Hicks RJ,. Samra JS,  Pavlakis N, Haghighi KS, Yip S, Donoghoe M, Friend C, Burge ME, Fawcett J, Harris M, Aghmesheh M, Joubert WL, Gebski V, Simes J, Goldstein D. Initial survival outcomes for the AGITG GAP study-a phase II study of perioperative Nab- paclitaxel and gemcitabine for resectable pancreatic ductal adenocarcinoma (PDAC). American Society of Clinical Oncology Annual Meeting, Chicago 2016 (abstract 4105)(poster).

Toohey K, Pumpa K, Cooke J, Yip D, Craft P, Arnolda L, Semple S. Low-volume high intensity interval training versus continuous moderate intensity training: Effects on health outcomes and cardiovascular disease risk factors in cancer survivors: A pilot study. Exercise and Sport Science Australia Conference: Research to Practice, Melbourne 2016.

Beatty L, Kemp E, Binnion C, Butow P, Tuner J, Milne D, Yates P, Yip D, Lambert S, Koczwara B. Finding My Way: Uptake and predictors of adherence to an online psychological intervention for cancer-related distress. Multinational Association of Supportive Care in Cancer Annual Meeting, Adelaide 2016 (Poster presentation).

Lok SW, Pellegrini L, Greenberg S, Oakman C, Green M, Foo S, Richardson G, Yip D, Nott L, Gibbs P, De Boer R. TABITHA-A prospective multi-site registry capturing treatment and outcome data in the metastatic Her2 positive breast cancer patient. Medical Oncology Group of Australia Annual Scientific Meeting, Gold Coast 2016 (Poster presentation).

Strach MC, Lee M, Lomax AJ, Ng M, Guerrieri M, Prasanna T, Wong Hui-li, Lee B, McKendrick J, Lim L, Kosmider S, Tie J, Yip D, Nott L, Johns J, Harold M, Gibbs P, Wong R. Treatment sequencing and outcomes in synchronous metastastic rectal cancer. Medical Oncology Group of Australia Annual Scientific Meeting, Gold Coast 2016 (Poster presentation).

Nguyen, B, Janz-Robinson, E, Arora, A, Ali, S. Anti-PD1 therapy in patients with metastatic melanoma – A single centre experience Medical Oncology Group of Australia Annual Scientific Meeting, Gold Coast, 2016 (Poster presentation).

Nguyen, B, Ali, S. Unusual side effects of anti-PD1 checkpoint inhibitors in the treatment of stage IV melanoma. Medical Oncology Group of Australia Annual Scientific Meeting, Gold Coast 2016 (poster presentation).

Nguyen, B., Montgomery, R., Fadia, M., Wang, J., Ali, S.. PDL1 Expression Associated with worse survival outcome in Malignant Pleural Mesothelioma. European Society of Medical Oncology Asia Congress, Singapore 2016.

Dua D, Yip D, Choudhry M, Ashmore T, Chapman M, Pranavan G, Paramadhathil A. Develop a service model for a geriatric oncology clinic with cancer social worker co-ordination. International Society of Geriatric Oncology Annual Conference, Warsaw 2017 (Poster).

Dua D, Yip D, Choudhry M, Ashmore T, Chapman M, Pranavan G, Paramadhathil A. Develop a service model for a geriatric oncology clinic with cancer social worker co-ordination. Canberra Health Annual Research Meeting, Warsaw 2017 (Poster).

Lee B, Anton A, Lee M, Wong R, Parente P, Shapiro JD, Yip D, Steel SA, Nott LM, Stefanou G, Iddawela MY, Gibbs P, Tran B Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC). GI Cancer Symposium 2017 (Abstract 728) (Poster presentation).

Strach MC, Lee M, Lomax AJ, Ng M, Guerrieri M, Prasanna T, Wong HL, Lee B, McKendrick J,L Lim, Kosmider S, Tie J, Yip D, Nott L, Johns J, Harold M, Gibbs P, Wong R. Treatment sequencing and outcomes in synchronous metastatic rectal cancer. GI Cancer Symposium 2017 (Abstract 750 ) (Poster presentation).

Lee M, Lok SW, Turner NH, Day D, Greenberg S, Green M, Foo SS, Yip D, Nott LM, Gibbs P, De Boer RH. A real-world registry to evaluate HER2-directed therapy in Australian patients with metastatic breast cancer. American Society of Clinical Oncology Annual Meeting, Chicago 2017, e12515.

Prasanna T, Craft PS, Chua YJ, Karapetis CS, Gibbs P, Wong R, Tie J, Roder D, Jay Price TJ, Padbury R, Piantadosi C,Yip D. The outcome of patients (pts) with metastatic colorectal cancer (mCRC) based on site of metastases (mets) and the impact of molecular markers and site of primary cancer on metastatic pattern. American Society of Clinical Oncology Annual Meeting, Chicago 2017, Abstract 3560 (Poster presentation).

Tie J, Cohen J, Wang Y, Li L, Kinde I, Elsaleh H,Wong R, Kosmider S, Yip D, Lee M,Tran B, Burge ME, Goldstein D, Singh MS, Diaz LA, Tomasetti C, Papadopoulos N, Kinzler KW,Vogelstein B, Gibbs P. The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC). American Society of Clinical Oncology Annual Meeting, Chicago 2017, Abstract 3521 (Oral presentation).

Maish W, Randhawa M, Pranavan G . Efficacy and safety of metronomic procarbazine and temozolomide in the treatment of recurrent glioblastoma multiforme: a retrospective analysis. Asian Society for Neuro-Oncology (ASNO), Osaka, Japan 2017 (Poster)

Dumbrava, M. I., De Boer, R., Wen Lok, S., Gibbs, P., Greenberg, S., Pellgrini, L., Yip, D. & Malik, L..General characteristics, patterns of relapse and treatment outcomes of patients with HER2 amplified metastatic breast cancer (MBC) who are hormone receptor positive (HR+) versus hormone receptor negative (HR-) (47521). Poster session presented at the Clinical Oncology Society of Australia Annual Scientific Meeting. Sydney, 2017 (Poster Presentation).

Page last updated on: 16 Nov 2018